Loss of ACE2 accelerates time-dependent glomerular and tubulointerstitial damage in streptozotocin-induced diabetic mice (Q43148851)

14 November 2017

title

Loss of ACE2 accelerates time-dependent glomerular and tubulointerstitial damage in streptozotocin-induced diabetic mice (English)

1 reference

14 November 2017

9

1 reference

14 November 2017

Atsushi Shiota

1

1 reference

14 November 2017

Koichi Yamamoto

2

1 reference

14 November 2017

Mitsuru Ohishi

3

1 reference

14 November 2017

Yuji Tatara

4

1 reference

14 November 2017

Miyuki Ohnishi

5

1 reference

14 November 2017

Yoshihiro Maekawa

6

1 reference

14 November 2017

Yoshihiro Iwamoto

7

1 reference

14 November 2017

Masao Takeda

8

1 reference

14 November 2017

language of work or name

1 reference

26 February 2010

1 reference

14 November 2017

published in

Hypertension Research

1 reference

14 November 2017

volume

33

1 reference

14 November 2017

issue

4

1 reference

14 November 2017

page(s)

298-307

1 reference

https://scigraph.springernature.com/pub.10.1038/hr.2009.231

14 November 2017

exact match

0 references

cites work

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

The intrarenal renin-angiotensin system and diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

Urinary Smad1 is a novel marker to predict later onset of mesangial matrix expansion in diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

Reduction of albuminuria by angiotensin receptor blocker beyond blood pressure lowering: evaluation in megsin/receptor for advanced glycation end products/inducible nitric oxide synthase triple transgenic diabetic nephropathy mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

In vivo imaging of oxidative stress in the kidney of diabetic mice and its normalization by angiotensin II type 1 receptor blocker

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

Kidney expression of glutathione peroxidase-1 is not protective against streptozotocin-induced diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

JunD protects against chronic kidney disease by regulating paracrine mitogens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

Angiotensin-converting enzyme 2 is an essential regulator of heart function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

Angiotensin-converting enzyme 2 gene targeting studies in mice: mixed messages

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

Positionally cloned gene for a novel glomerular protein--nephrin--is mutated in congenital nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

Structure of the gene for congenital nephrotic syndrome of the finnish type (NPHS1) and characterization of mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

Vascular endothelial growth factor (VEGF) and soluble VEGF receptor FLT-1 in diabetic nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: effects of an ACE inhibitor and an angiotensin II receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

Genetically altered animal models for Mas and angiotensin-(1-7).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

7 January 2021

Angiotensin II stimulates alpha3(IV) collagen production in mouse podocytes via TGF-beta and VEGF signalling: implications for diabetic glomerulopathy

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

7 January 2021

Effects of angiotensin-(1-7) blockade on renal function in rats with enhanced intrarenal Ang II activity

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

7 January 2021

Intrarenal infusion of angiotensin-(1-7) modulates renal functional responses to exogenous angiotensin II in the rat

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

7 January 2021

Angiotensin II production and distribution in the kidney: I. A kinetic model

1 reference

https://api.crossref.org/works/10.1038%2FHR.2009.231

7 January 2021

Identifiers

DOI

10.1038/HR.2009.231

1 reference

14 November 2017

1 reference